Clinical trials: Uncomplicated Malaria, open to volunteers
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
- Trial name
- PLATINUM (NCT05750628)
- Testing
- INE963, KAE609 (Cipargamin), SoC (Coartem)
- Where
- 12 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Pregnancy, Malaria, Antepartum
Safety of Antimalarials in the FIRst trimEster
The SAFIRE study aims to find effective treatments with acceptable safety for malaria in early pregnancy, a particularly sensitive time for the adverse consequences of malaria in pregnancy for both mother and baby.
- Conditions
- Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)
- Trial name
- SAFIRE (NCT06962319)
- Testing
- dihydroartemisinin-piperaquine (DP), Pyronaridine-artesunate (PA), Artemether-lumefantrine
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 1,510 people
- Sponsor
- Liverpool School of Tropical Medicine
Uncomplicated Malaria
Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07403643
- Testing
- Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 60 people
- Sponsor
- Curtin University
Uncomplicated P. Vivax Mono-infection
Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax
This study is to conduct a clinical trial of tafenoquine combinations to compare the rates of therapeutic efficacy of dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine to chloroquine plus tafenoquine in…
- Trial name
- NCT07533136
- Testing
- Tafenoquine (TQ), Chloroquine (CQ), Dihydroartemisinin-piperaquine (DHA-PPQ)
- Where
- Thailand
- Volunteers
- 300 people
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Malaria
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria
This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to <5 kg with uncomplicated malaria due to Plasmodium…
- Trial name
- NCT07713602
- Testing
- Coartem® Baby
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Malaria (Plasmodium Falciparum)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL).
- Trial name
- NCT07559370
- Testing
- Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate
- Where
- Kenya
- Volunteers
- 1,116 people
- Sponsor
- Victoria Biomedical Research Institute
Uncomplicated Plasmodium Falciparum Malaria
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs…
- Trial name
- FD-TACT (NCT05951595)
- Testing
- Artemether-Lumefantrine-Amodiaquine (ALAQ), Artemether-Lumefantrine (AL), Artesunate-Amodiaquine (ASAQ)
- Where
- Rwanda
- Volunteers
- 1,680 people
- Sponsor
- University of Oxford
Malaria
Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
This non-interventional qualitative study will examine factors that influence the adoption of a novel malaria treatment in Côte d'Ivoire, Ghana, and Rwanda.
- Trial name
- NCT07896746
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Falciparum
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
- Trial name
- NCT07545681
- Testing
- GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute